Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748615 | 0.80 | HTR2A (0.39) | — | |
| SCHEMBL6745374 | 0.80 | CES1 (0.35) | — | |
| SCHEMBL6749822 | 0.76 | KDM1A (0.49) | ACHEMAOASCN8ACHRM2SIGMAR1 | |
| SCHEMBL6746830 | 0.75 | ACHE (0.39) | ACHEMAOASCN8ACHRM2SIGMAR1 | |
| SCHEMBL6748820 | 0.67 | DPP7 (0.36) | ACHEMAOASCN8ACHRM2SIGMAR1 | |
| SCHEMBL8541296 | 0.67 | ACHE (0.88) | ACHE | |
| SCHEMBL9492327 | 0.65 | CHRM2 (0.63) | ACHEMAOASCN8ACHRM2SIGMAR1 | |
| SCHEMBL6045316 | 0.65 | SIGMAR1 (0.53) | ACHEMAOACHRM2SIGMAR1 | |
| SCHEMBL13985121 | 0.64 | ACHE (0.72) | ACHE | |
| SCHEMBL4932707 | 0.62 | MAOA (0.95) | MAOACHRM2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703388-B2 | DIBENZODIAZEPINE DERIVATIVES; ANTIHISTAMINES, LEUKOTRIENE INHIBITORS, ANTIALLERGENS, ANTIASTHMATICS; HAY FEVER, ATOPIC DERMATITIS, AND URTICARIA TREATMENT | EISAI CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20030171367-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | EISAI CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| US-6489336-B2 | PHENOTHIAZINE, ACRIDAN, ACRIDONE OXIME, ACRIDONE HYDRAZONE, OR DIBENZODIAZEPINE DERIVATIVES; TYROSINE KINASE INHIBITORS; TREATING ALLERGIC DISEASES | EISAI CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020103189-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | EISAI CO., LTD. | 2002-08-01 | — | — | US | disclosed |
| US-6333322-B1 | FOR THERAPY OF ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, URTICARIA, HAY FEVER, GASTROINTESTINAL ALLERGY AND FOOD ALLERGY | EISAI CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0889037-A1 | NITROGENOUS TRICYCLIC COMPOUNDS AND DRUGS COMPRISING THE SAME | Eisai Co., Ltd. (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171367-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | HRH2, HRH1, HRH4 | ACHE 783/4885MAOA 137/4885SCN8A 3189/4885 |
| US-20020103189-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | HRH2, HRH1, HRH4 | ACHE 783/4885MAOA 137/4885SCN8A 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.